ISSN 1725-2423

Official Journal of the European Union

C 287

Volume 49

English edition

Information and Notices

24 November 2006

Notice No | Contents | Page

EN

[1] Text with EEA relevance

I

(Information)

COMMISSION

Euro exchange rates ([1])

23 November 2006

(2006/C 287/01)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,2953	SIT	Slovenian tolar	239,66
JPY	Japanese yen	150,61	SKK	Slovak koruna	35,653
DKK	Danish krone	7,4547	TRY	Turkish lira	1,9080
GBP	Pound sterling	0,67650	AUD	Australian dollar	1,6725
SEK	Swedish krona	9,0595	CAD	Canadian dollar	1,4769
CHF	Swiss franc	1,5843	HKD	Hong Kong dollar	10,0822
ISK	Iceland króna	91,78	NZD	New Zealand dollar	1,9321
NOK	Norwegian krone	8,2600	SGD	Singapore dollar	2,0057
BGN	Bulgarian lev	1,9558	KRW	South Korean won	1 205,21
CYP	Cyprus pound	0,5779	ZAR	South African rand	9,3050
CZK	Czech koruna	27,950	CNY	Chinese yuan renminbi	10,1836
EEK	Estonian kroon	15,6466	HRK	Croatian kuna	7,3433
HUF	Hungarian forint	258,63	IDR	Indonesian rupiah	11 826,74
LTL	Lithuanian litas	3,4528	MYR	Malaysian ringgit	4,7117
LVL	Latvian lats	0,6974	PHP	Philippine peso	64,396
MTL	Maltese lira	0,4293	RUB	Russian rouble	34,3820
PLN	Polish zloty	3,8211	THB	Thai baht	47,319
RON	Romanian leu	3,4874			

([1]) *Source:* reference exchange rate published by the ECB.

Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs

(2006/C 287/02)

This publication confers the right to object to the application pursuant to Article 7 of Council Regulation (EC) No 510/2006. Statements of objection must reach the Commission within six months from the date of this publication.

SUMMARY

COUNCIL REGULATION (EC) No 510/2006

Application for registration according to Article 5 and Article 17(2)

'PIMENTÓN DE LA VERA'

EC No: ES/PDO/005/0321/29.10.2003

PDO (X) PGI ( )

This summary has been drawn up for information only. For full details, interested parties are invited to consult the full version of the product specification obtainable from the national authorities indicated in section 1 or from the European Commission ([1]).

1. *Responsible department in the Member State:*

Name:	Subdirección General de Calidad y Promoción Agroalimentaria — Dirección General de Industria Agroalimentaria y Alimentación — Secretaría General de Agricultura y Alimentación del Ministerio de Agricultura, Pesca y Alimentación de España.
Address:	Infanta Isabel, 1 E-28071 Madrid
Tel.:	(34) 913 47 53 94
Fax:	(34) 913 47 54 10
e-mail:	sgcaproagro@mapya.es

2. *Group:*

Name:	D. Manuel Fernández Amor, con D.N.I. nº 5.602.884-S, y otros.
Address:	«Unión de Productores de Pimentón, Sociedad Cooperativa» Polígono Industrial «El Pocito», Calle E, Parcela E-7, E-10400 Jaraíz de la Vera (Cáceres)
Tel.:	(34) 927 46 00 12
Fax:	(34) 927 17 00 71
e-mail:	—
Composition:	Producers/processors (X) Other ( )

3. *Type of product:*

Class 1.8 — Other Annex II products (spices) — Paprika

4. *Specification (summary of requirements under Article 4(2))*

4.1. Name: 'Pimentón de la Vera'

([1]) European Commission, Directorate-General for Agriculture and Rural Development, Agricultural Product Quality Policy, B-1049 Brussels.

4.2. Description: Paprika with the Protected Designation of Origin 'Pimentón de la Vera' means the product from grinding the totally red fruits of the Jaranda, Jariza and Jeromín varieties of the 'Ocales' group, and the Bola variety, of the botanical species *Capsicum annum* L. and *Capsicum longum* L. collected when they are ripe, healthy and clean and have the colour typical of the variety, free of pests or disease, dried using oak and/or holm oak wood in the traditional fashion of the Vera, and which comes from the designated area of production.

La Vera paprika is a product with a smoky taste and aroma which is made intense and penetrating by the process of drying the chillies using smoke. It is deep red in colour and shiny. It imparts its colour vigorously, more in the case of the varieties from the Ocales group than the Bola variety. Taste, aroma and colour are very stable over time, mainly because of the slow and gentle drying process used.

Depending on taste, the paprika may be divided into three groups:

— Sweet paprika: gentle taste, completely sweet. Made from the Bola and Jaranda varieties.

— Ocal or sweet/hot paprika: slightly sharp on the palate. Made from the Jaranda and Jariza varieties.

— Hot paprika: decidedly hot on the palate. Made from the Jeromín, Jariza and Jaranda varieties.

Physico-chemical characteristics: Pimentón de la Vera is defined by the following physical-chemical characteristics:

— Size of the seed: the paprika seed must be milled so that it passes through a No 16 sieve or screen on the ASTM scale (equivalent to a 1,19 mm mesh).

— Analytical characteristics:

Maximum water content	14
Maximum ether extract of dry matter	23
Maximum raw fibre in dry matter	28
Maximum ash in dry matter:	
— Total (maximum)	9
— Insoluble (maximum)	1
Colour (*), ASTA units: minimum	90

(*) At the time of milling

— Food ingredients: edible sunflower oil (a maximum of 3 % by weight of the dry product) may occasionally be added to the powdered paprika to give the final product consistency and shine. The addition of oil does not affect the specific character of the paprika and so no specific geographical origin is specified for the oil.

— The prepared product must be totally free from seeds, veins, flower heads and stalks from varieties of chillies other than those authorised for each of the three groups of paprika, artificial colouring matters and other substances affecting the parameters defining this spice.

— The proportion of seeds, veins, flower heads and stalks from the authorised varieties of chillies must be less than that of the rest of the fruit.

4.3. Geographical area: The area of production of chillies for the production of paprika under the 'Pimentón de la Vera' Protected Designation of Origin comprises the following municipalities of the natural areas known as La Vera, Campo Arañuelo, Valle del Ambroz and Valle del Alagón, in the north of the Province of Cáceres: Abadía, Aldeanueva de la Vera, Aldeanueva del Camino, Aldehuela del Jerte, Arroyomolinos de la Vera, Carcaboso, Casas del Monte, Casatejada, Casillas de Coria, Cilleros, Collado, Coria, Cuacos de Yuste, El Toril, Galisteo, Garganta la Olla Gargantilla, Granja de Granadilla, Guijo de Galisteo, Guijo de Granadilla, Guijo de Santa Bárbara, Holguera, Jaraíz de la Vera, Jarandilla de la Vera, Losar de la Vera, Madrigal de la Vera, Majadas de Tiétar, Malpartida de Plasencia, Montehermoso, Moraleja, Morcillo, Navalmoral de la Mata, Pasarón de la Vera, Plasencia, Riolobos, Robledillo de la Vera, Rosalejo, Saucedilla, Segura de Toro, Serrejón, Talaveruela de la Vera, Talayuela, Tejeda de Tiétar, Torrejoncillo, Torremenga, Valdeobispo, Valverde de la Vera, Viandar de la Vera, Villanueva de la Vera, Zarza de Granadilla.

The area for preparation and packaging fully coincides with the area of production.

All the procedures for the production of 'Pimentón de la Vera' must be carried out in the municipalities listed above, i.e. growing, drying and processing all take place within this geographical area. This requirement is intended to provide greater guarantees of the origin, traceability and quality of the final product.

4.4. Proof of origin: Protected la Vera paprika is produced in registered establishments from dried chillies from registered holdings in the area of production; once it has passed the checks laid down, it is marketed under the Protected Designation of Origin 'Pimentón de la Vera' with a numbered secondary label. The chillies used come from the Jaranda, Jariza and Jeromín varieties in the 'Ocales' group and from the Bola variety.

4.5. Method of production: This begins with seed planting from the end of February to early April, to secure chilli plants which will be finally planted out roughly between 15 May and 10 June.

The land where they are to be planted out is first properly prepared to provide the best conditions with any hard subsurface layers and clods broken up, hoeing and the addition of organic and mineral fertilisers and the shaping of the soil.

Planting is carried out by hand or using mechanical transplanters. The plants are then watered copiously to promote good root formation.

Depending on the holding, this is done by gravity, sprinkling or in some cases local irrigation systems.

Once the fruit is ripe it is harvested by hand and taken for drying on the holding itself. Water is removed by means of a vertical current of air with a fire beneath (smoke-drying). This is done by the farmer himself.

This system is conducive to slow, gentle, non-aggressive drying so that within 10 to 15 days the water content of the fruit falls from 80 % to under 15 %. The final product obtained ('cáscara') has a smoky taste and aroma and a very stable colour — these are features of the system of drying used.

The 'cáscara' is then taken to local mills for grinding on emery stones. The ground paprika is then passed through horizontally positioned stones known as 'piedras de transmitir'. Occasionally, vegetable oil is added at this point up to the maximum proportion laid down in point 4.2.1.3 of this Summary. The addition of oil does not affect the specific character of the paprika. Finally, it is packaged and labelled and so is ready for marketing

4.6. Link: The first references to the cultivation of La Vera paprika date from the sixteenth-century, when it was cultivated in the Monastery of Yuste (Cuacos de Yuste, La Vera district) by the Hieronymite friars.

Cultivation gradually spread from La Vera to neighbouring areas, the Campo Arañuelo, Valle del Ambroz and Valle del Alagón, becoming steadily more valued by farmers because of its profitability.

The industrial process for obtaining paprika began at the end of the seventeenth-century and expanded substantially in the mid-eighteenth-century. At that time the chillies were ground in water-powered flour mills located by streams. The coming of electricity to La Vera meant that electric mills could be used, leading to substantial improvements in the industry, which began to concentrate on producing paprika.

The varieties of chilli used for producing paprika are native ones belonging to the botanical species *Capsicum annum* L. and *Capsicum longum* L., the former being slightly oblate and the latter longer. The first group includes the Bola varieties-population and the second the Ocales varieties-population, also known as Agridulce de la Vera. These are very hardy varieties and very well adapted to the soil and climate of the area. Their splendid acclimatisation is the reason why they have not been replaced by varieties from elsewhere. Another important factor justifying the use of local vegetative material is that it is completely adapted to the system of drying by smoke, used in La Vera from the seventeenth-century to the present day.

The protection provided by the Sierra de Gredos, the properties of the soils, which are loose and totally free from salt, the quality of the water used for irrigation, which is also salt-free, and the features of the microclimate of the area of production permit cultivation of these indigenous varieties which produce fruit which gives a particular taste to the paprika obtained from them.

To the taste of the variety is added that of the smoking, a system of drying related to the climatic features of the area, where sun-drying is not possible, and which gives the paprika its characteristic taste and aroma as well as very stable colour.

The use of indigenous varieties, smoke-drying and the use of stone mills in La Vera since the seventeenth-century differentiates the paprika produced there from that produced elsewhere in the world. It has its own personality, so that the paprika produced in the north of Cáceres using the system described above is known as La Vera paprika.

4.7. Inspection body:

Name: Consejo Regulador de la Denominación de Origen Protegida «Pimentón de la Vera»

Address: Avda. de la Constitución, 65
E-10400 Jaraíz de la Vera (Cáceres)

Tel.: (34) 927 17 02 72

Fax: (34) 927 17 02 72

e-mail: info@pimentonvera-origen.com

The inspection body for the 'Pimentón de la Vera' PDO satisfies standard UNE-EN 45.011.

4.8. Labelling: Commercial labels used by each producing industry must be approved by the inspection body. They must bear the words: 'Denominación de Origin Protegida "Pimentón de la Vera"'.

All La Vera paprika certified as having a Protected Designation of Origin put up for consumption must be identified by the logo registered and owned by the Regulatory Board and the numbered secondary label — otherwise it may not be sold. It must be impossible to reuse the numbered secondary label.

4.9. National requirements:

— Law No 25/1970 of 2 December 1970 laying down rules on vineyards, wine and spirit drinks and the implementing rules approved by Decree No 835/1972 of 23 March 1972.

— Decree No 835/1972 of 28 March 1972 laying down detailed rules for the application of Law No 25/1970.

— Order of 25 January 1994 establishing the correspondence between Spanish legislation and Regulation (EEC) No 2081/92 on designations of origin and geographical indications for food products.

— Royal Decree No 1643/99 of 22 October 1999 on the procedure for submitting applications for entry on the Community Register of Protected Designations of Origin and Protected Geographical Indications.

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1.10.2006 to 31.10.2006

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1]*)*

(2006/C 287/03)

— Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
4.10.2006	Abilify	Otsuka Pharmaceutical Europe Ltd Hunton House Highbridge Business Park Oxford Road Uxbridge Middlesex UB8 1HU United Kingdom	EU/1/04/276/036	6.10.2006
4.10.2006	Abilify	Otsuka Pharmaceutical Europe Ltd Hunton House Highbridge Business Park Oxford Road Uxbridge Middlesex UB8 1HU United Kingdom	EU/1/04/276/036	6.10.2006
6.10.2006	Travatan	Alcon Laboratories (UK) Ltd. Boundary Way Hemel Hempstead Herts HP2 7UD United Kingdom	EU/1/01/199/001-002	10.10.2006
11.10.2006	Invirase	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/96/026/001-002	13.10.2006
17.10.2006	Cetrotide	Serono Europe Ltd. 56, Marsh Wall London E14 9TP United Kingdom	EU/1/99/100/001-003	19.10.2006
19.10.2006	Zometa	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/01/176/001-006	23.10.2006
19.10.2006	Zevalin	Schering AG Müllerstrasse 170-178 D-13342 Berlin	EU/1/03/264/001	23.10.2006
20.10.2006	Herceptin	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/00/145/001	24.10.2006

[1] OJ L 136 of 30 April 2004, page 1

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
20.10.2006	PritorPlus	Bayer HealthCare AG D-51368 Leverkusen	EU/1/02/215/001-012	24.10.2006
20.10.2006	Enbrel	Wyeth Europa Limited Huntercombe Lane South Taplow Maidenhead Berkshire, SL6 0PH United Kingdom	EU/1/99/126/001-018	24.10.2006
20.10.2006	Caelyx	Schering Plough Europe Rue de Stalle 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/96/011/001-004	24.10.2006
20.10.2006	Avonex	Biogen Idec Ltd 5 Roxborough Way Foundation Park Maidenhead Berkshire SL6 3UD United Kingdom	EU/1/97/033/001-003	24.10.2006
20.10.2006	Faslodex	AstraZeneca UK Limited Alderley Park Macclesfield Cheshire SK10 4TG United Kingdom	EU/1/03/269/001	24.10.2006
20.10.2006	ViraferonPeg	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/00/132/001-050	24.10.2006
23.10.2006	Taxotere	Aventis Pharma S.A., 20 Avenue Raymond Aron, Antony Cedex 92165, France	EU/1/95/002/001-002	25.10.2006
23.10.2006	PhotoBarr	Axcan Pharma International BV Engelenkampstraat 72 6131 JJ Sittard Nederland	EU/1/04/272/001-002	25.10.2006
23.10.2006	Dynepo	Shire Pharmaceutical Contracts Ltd Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom	EU/1/02/211/001-005	26.10.2006
24.10.2006	PegIntron	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/00/131/001-050	25.10.2006
24.10.2006	AVANDIA	SmithKline Beecham plc 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom	EU/1/00/137/002-018	26.10.2006

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
24.10.2006	Aclasta	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/05/308/001-002	26.10.2006
24.10.2006	Prometax	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/98/092/001-018	26.10.2006
24.10.2006	Invanz	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/02/216/001-002	26.10.2006
24.10.2006	Apidra	Sanofi-Aventis Deutschland GmbH Brueningstrasse, 50 D-65926 Frankfurt am Main	EU/1/04/285/013-020	26.10.2006
24.10.2006	Fuzeon	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/03/252/001-003	26.10.2006
24.10.2006	Avandamet	SmithKline Beecham plc 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom	EU/1/03/258/001-022	26.10.2006
26.10.2006	Ketek	Aventis Pharma S.A. 20 Avenue Raymond Aron F-92160 Antony	EU/1/01/191/001-005	30.10.2006
26.10.2006	Levviax	Aventis Pharma S.A. 20 Avenue Raymond Aron F-92160 Antony	EU/1/01/192/001-005	30.10.2006
26.10.2006	Actos	Takeda Global Research and Development Centre (Europe) Ltd, Arundel Great Court 2 Arundel Street London WC2R 3DA United Kingdom	EU/1/00/150/001-024	30.10.2006
26.10.2006	Glustin	Takeda Global Research and Development Centre (Europe) Ltd Arundel Great Court 2 Arundel Street London WC2R 3DA United Kingdom	EU/1/00/151/001-022	30.10.2006
26.10.2006	Sustiva	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UD8 1DH United Kingdom	EU/1/99/110/001-009	30.10.2006
26.10.2006	Stocrin	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/99/111/001-009	30.10.2006

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
26.10.2006	Exelon	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/98/066/001-018	30.10.2006
26.10.2006	Helixate NexGen	Bayer AG D-51368 Leverkusen,	EU/1/00/144/001-003	30.10.2006
26.10.2006	Vfend	Pfizer Limited, Sandwich Kent CT13 9NJ United Kingdom	EU/1/02/212/001-026	30.10.2006
27.10.2006	Pritor	Bayer HealthCare AG D-51368 Leverkusen	EU/1/98/089/001-019	31.10.2006
27.10.2006	Ariclaim	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten Nederland Boehringer Ingelheim International GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein	EU/1/04/283/001-007	31.10.2006
27.10.2006	Rebetol	Schering Plough Europe Rue de Stalle 73 B-1180 Bruxelles Stallestraat, 73 B-1180 Brussel	EU/1/99/107/001-005	31.10.2006
27.10.2006	Remicade	Centocor B.V. Einsteinweg 101 2333 CB Leiden Nederland	EU/1/99/116/001-003	31.10.2006
27.10.2006	Avaglim	SmithKline Beecham plc 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom	EU/1/06/349/001-008	31.10.2006
27.10.2006	Viramune	Boehringer Ingelheim International GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein	EU/1/97/055/001-003	31.10.2006
27.10.2006	Invirase	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/96/026/001-002	31.10.2006
27.10.2006	Tracleer	Actelion Registration Ltd BSI Building 13th Floor 389 Chiswick High Road London W4 4AL United Kingdom	EU/1/02/220/001-005	31.10.2006
30.10.2006	FOSAVANCE	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/05/310/001-005	1.11.2006
30.10.2006	Lyrica	PFIZER Ltd, Ramsgate Road Sandwich Kent CT 13 9NJ United Kingdom	EU/1/04/279/001-035	1.11.2006

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
30.10.2006	NutropinAq	IPSEN Limited, 190 Bath Road Slough, Berkshire SLI 3XE United Kingdom	EU/1/00/164/003-005	1.11.2006
30.10.2006	Keppra	UCB S.A. Allée de la recherche 60 B-Bruxelles 1070 Researchdreef, 60 B-Brussel 1070	EU/1/00/146/001-030	3.11.2006
30.10.2006	Noxafil	SP Europe Rue de Stalle, 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/05/320/001	2.11.2006
30.10.2006	Posaconazole SP	SP Europe Rue de Stalle 73 B-1180 Bruxelles Stallestraat 73 — B-1180 Brussel	EU/1/05/321/001	2.11.2006
30.10.2006	Nespo	Dompé Biotec S.p.A. Via San Martino 12 I-20122 Milano	EU/1/01/184/001-068	2.11.2006
30.10.2006	Aranesp	Amgen Europe B.V. Minervum 7061 4817 ZK Breda Nederland	EU/1/01/185/001-068	1.11.2006
31.10.2006	Lantus	Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main	EU/1/00/134/001-037	14.11.2006
31.10.2006	Insuman	Aventis Pharma Deutschland GmbH Brueningstrasse 50 D-65926 Frankfurt am Main	EU/1/97/030/065-084	6.11.2006
31.10.2006	Optruma	Eli Lilly Nederland BV Grootslag 1-5 3991 RA Houten Nederland	EU/1/98/074/001-004	6.11.2006
31.10.2006	Evista	Eli Lilly Nederland BV Grootslag 1-5 3991 RA Houten Nederland	EU/1/98/073/001-004	6.11.2006
31.10.2006	Telzir	Glaxo Group Ltd. Greenford Road Greenford Middlesex UB6 0NN United Kingdom	EU/1/04/282/001-002	7.11.2006

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
7, Westferry Circus, Canary Wharf
London E14 4HB
United Kingdom

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1.10.2006 to 31.10.2006

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC [1] or Article 38 of Directive 2001/82/EC [2])

(2006/C 287/04)

— Issuing, maintenance or modification of a national marketing authorisation

Date of the decision	Name(s) of the medicinal product	Holder(s) of the marketing authorization	Member State concerned	Date of notification
11.10.2006	Doxastad (doxazosin) Art 29	See Annex I	See Annex I	13.10.2006
11.10.2006	Doxazosin Winthrop (doxazosin) Art 29 -	See Annex II	See Annex II	13.10.2006
11.10.2006	Cardoreg (doxazosin) Art 29	See Annex III	See Annex III	13.10.2006
11.10.2006	Doxagamma (doxazosin) Art 29	See Annex IV	See Annex IV	13.10.2006
11.10.2006	Doxazosin Retard Arrow (doxazosin) Art 29	See Annex V	See Annex V	13.10.2006
13.10.2006	Cobactan DC Art 39	See Annex VI	See Annex VI	16.10.2006

[1] OJ L 311, 28.11.2001, p. 67.
[2] OJ L 311, 28.11.2001, p. 1.

ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S) OF THE MEDICINAL PRODUCT(S), ROUTE(S) OF ADMINISTRATION, APPLICANT(S) MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name	Strength	Pharmaceutical Form	Route of administration
Estonia		STADA Arzneimittel AG Stadastr. 2-18, D-61118 Bad Vilbel Tél: 0049 6101 603301 Fax: 0049 6101 603151	Doxalfa 4 mg toimeainet prolongeeritult vabastavad tabletid	4 mg	Prolonged-release tablet	Oral
Latvia		STADA Arzneimittel AG Stadastr. 2-18, D-61118 Bad Vilbel Tél.: 0049 6101 603301 Fax: 0049 6101 603151	Doxalfa 4 mg ilgstošās darbības tabletes	4 mg	Prolonged-release tablet	Oral
Lithuania		STADA Arzneimittel AG Stadastr. 2-18, D-61118 Bad Vilbel Tél: 0049 6101 603301 Fax: 0049 6101 603151	Doxalfa 4 mg pailginto atpalaidavimo tabletės	4 mg	Prolonged-release tablet	Oral
Netherlands		Cerntrafarm Services B.V. Nieuwe Donk 9 4879 AC Etten-Leur Nederland Tél: 0031 765 081000 Fax: 0031 765 035614	Doxazosine retard CF 4mg, tabletten met gereguleerde afgifte	4 mg	Prolonged-release tablet	Oral
Spain		Laboratorio STADA, S.L. Frederic Mompou, 5 08960 Sant Just Desvern E-Barcelone Tél: 0034 93 47 38889 Fax: 0034 93 47 37495	DOXAZOSINA NEO STADA 4 mg comprimidos de liberación prolongada EEG	4 mg	Prolonged-release tablet	Oral
Sweden	STADA Arzneimittel AG Stadastr. 2-18, D.61118 Bad Vilbel Tél: 0049 6101 603301 Fax: 0049 6101 603151		Doxastad 4mg depottablett	4 mg	Prolonged-release tablet	Oral
United Kingdom		Genus Pharmaceuticals Benham Valence, Speen Newbury Berkshire RG20 8LU United Kingdom Tél: 01635 568400 Fax: 01635 568401	Doxadura XL 4 mg	4 mg	Prolonged-release tablet	Oral

ANNEX II

LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S) OF THE MEDICINAL PRODUCT(S), ROUTE(S) OF ADMINISTRATION, APPLICANT(S) MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Name	Strength	Pharmaceutical Form	Route of administration
Denmark	Winthrop Pharmaceuticals UK Ltd 1 Onslow Street Guildford Surrey GU1 4YS Royaume-Uni Tél: 00 44 (0) 1483 55 48 31 Fax: 00 44 (0) 1483 55 48 31		Doxazosin 'Winthrop'	4 mg	Prolonged release tablets	Oral
Germany		Winthrop Arzneimittel GmbH Industriestrasse 10 82256 D-Furstenfeldbruck Tél: 0049 (0) 81 41 3572 324 Fax: 0049 (0) 81 41 3572 329	Doxazosin Winthrop 4 mg Retardtabletten	4 mg	Prolonged release tablets	Oral
Hungary		Chinoin Pharmaceuticals and Chemical Works Co Ltd 1045 H-Budapest, To utca 1-5 Tél: 0036 1 505 0000 Fax: 0036 1 505 0005	Doxazosin Winthrop 4mg Tablettes	4 mg	Prolonged release tablets	Oral
Poland		Winthrop Medicaments 1-13 Bd Romain Rolland F-75014, Paris Tél: 0033 (0) 1 57 63 33 33 Fax: 0033 (0) 1 57 63 33 30	DOXAWIN XL	4 mg	Prolonged release tablets	Oral
Slovakia		Winthrop Médicaments 1-13 Bd Romain Rolland F-75014 Paris Tél: 0033 (0) 1 57 63 33 33 Fax: 0033 (0) 1 57 63 33 30	Doxazosin Winthrop XL 4 mg	4 mg	Prolonged release tablets	Oral
Spain		Winthrop Pharmaceuticals UK Ltd 1 Onslow Street Guildford Surrey GU1 4YS United Kingdom Tél: 00 44 (0) 1483 55 48 31 Fax: 00 44 (0) 1483 55 48 31	Doxazosina WINTHROP 4 mg comprimidos de liberación prolongada EFG	4 mg	Prolonged release tablets	Oral
United Kingdom		Winthrop Pharmaceuticals UK Ltd 1 Onslow Street Guildford Surrey GU1 4YS United Kingdom	Slocinx XL 4mg Tablets	4 mg	Prolonged release tablets	Oral

ANNEX III

LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S) OF THE MEDICINAL PRODUCT(S), ROUTE(S) OF ADMINISTRATION, APPLICANT(S)/ MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name	Strength	Pharmaceutical Form	Route of administration
Czech Republic		Ratiopharm GmBH Graf-Arco-Strasse 3 D-89079 Ulm Tél: 0049 731 40202 Fax: 0049 731 4027330	Lansoprazol-ratiopharm 4 mg Hartkapseln	4 mg	Prolonged release tablets	Oral
Denmark	Pharmcom Oy Keijumaki 6B 30 FIN-02130 Espoo Tél: 00358 407 075670 Fax: 00358 94524872		Cardoreg 4 mg depotta-bletter	4 mg	Prolonged release tablets	Oral
Hungary		Ratiopharm Hungaria Kft. Uzoki utca 36/a H-1145 Budapest Tél: 0036 1 2732730 Fax: 0036 1 2732731	Doxazosin-ratiopharm retard 4 mg tabletta	4 mg	Prolonged release tablets	Oral
Poland		Ratiopharm GmBH Graf-Arco-Strasse 3 D-89079 Ulm Tél: 0049 731 40202 Fax: 0049 731 4027330	Doxazosin-ratiopharm retard PR4	4 mg	Prolonged release tablets	Oral
Slovakia		Ratiopharm GmBH Graf-Arco-Strasse 3 D-89079 Ulm Tél: 0049 731 40202 Fax:0049 731 4027330	Doxazosin-ratiopharm retard 4 mg	4 mg	Prolonged release tablets	Oral
United Kingdom		Ratiopharm GmBH Graf-Arco-Strasse 3 D-89079 Ulm Tél: 0049 731 40202 Fax: 0049 731 4027330	DoxaCard XL 4 mg prolonged release tablets	4 mg	Prolonged release tablets	Oral

ANNEX IV

LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S) OF THE MEDICINAL PRODUCT(S), ROUTE(S) OF ADMINISTRATION, APPLICANT(S)/MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name	Strength	Pharmaceutical Form	Route of administration
Denmark	Generics [UK] Ltd. Station Close Potters Bar Herts EN6 1TL. United Kingdom Tél: 00 44 1707 853000 Fax: 00 44 1707 650734		Doxagamma	4mg	Prolonged-release tablet	oral
United Kingdom		Generics [UK] Ltd., Station Close, Potters Bar, Herts,EN6 1TL. United Kingdom Tél: 00 44 1707 853000 Fax: 00 44 1707 650734	Doxzogen XL 4mg Tablets	4mg	Prolonged-release tablet	oral

ANNEX V

LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S) OF THE MEDICINAL PRODUCT(S), ROUTE(S) OF ADMINISTRATION, APPLICANT(S) MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Name	Strength	Pharmaceutical Form	Route of administration
Denmark	Arrow Generics UK Ltd Unit 2 Eastman Way Stevenage Hertfordshire, SG1 4SZ United Kingdom Tél.: 00 44 207 612 7612 Fax: 00 44 207 612 7620		Doxazosin 'Arrow', 4mg depottabletter	4 mg	Prolonged release tablets	Oral
Portugal		Arrowblue Produtos Farndacêuticos S.A. Torre Fernão Magalhães 10º Esq., Av. D. João II — P-Lisbonne Tél.: 00 351 21 896 51 05 Fax: 00 351 21896 51 05	Doxazosin Arrow 4mg comprimido de libertaçao prolongada	4 mg	Prolonged release tablets	Oral
Slovenia		Arrow Generics UK Ltd Unit 2 Eastman Way Stevenage Hertfordshire, SG1 4SZ United Kingdom Tél.: 00 44 207 612 7612 Fax: 00 44 207 612 7620	Doksazosin Arrow 4mg tablete s podaljšanim sproščanjem	4 mg	Prolonged release tablets	Oral
United Kingdom		Arrow Generics UK Ltd Unit 2 Eastman Way Stevenage Hertfordshire, SG1 4SZ United Kingdom Tél.: 00 44 207 612 7612 Fax: 00 44 207 612 7620	Cardozin XL 4mg	4 mg	Prolonged release tablets	Oral

ANNEX VI

LIST OF NAMES, PHARMACEUTICAL FORM OF THE MEDICINAL PRODUCTS, ANIMAL SPECIES, ROUTE OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Product invented name	Pharmaceutical form	Animal species	Frequency	Recommended dose	Withdrawal period (meat and milk)
Belgium	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Czech Republic	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC intramam susp. Ad us. Vet	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Germany	Intervet Deutschland GmbH Feldstr. 1a D-85716 Unterschleis-sheim	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Estonia	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Greece	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Spain	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
France	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC suspen-sion intramammaire	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Ireland	Intervet Ireland Magna Drive Magna Business Park Citywest Road IE-Dublin 24	Cephaguard DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Italy	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days

Member State	Marketing Authorisation Holder	Product invented name	Pharmaceutical form	Animal species	Frequency	Recommended dose	Withdrawal period (meat and milk)
Cyprus	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Latvia	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Lithuania	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Luxembourg	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Austria	Intervet Gesmbh Siemens-strasse 107 A -1210 Vienne	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Poland	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Portugal	Intervet Portugal, Lda. Estrada Nacional 249 PT-2725-397 Mem Martins	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Slovenia	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
Slovakia	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days
United Kingdom	Intervet International B.V. Wim de Körverstraat 35 NL -5831 AN Boxmeer	Cobactan DC	Intramammary ointment	Dairy cows	Single dose	150 mg cefquinome	Meat and offal: 2 days Milk: 49 days

Publication of decisions by Member States to grant or revoke operating licenses pursuant to Article 13(4) of Regulation No 2407/92 on licensing of air carriers [1] [2]

(2006/C 287/05)

(Text with EEA relevance)

AUSTRIA

Operating licences revoked

Category B: Operating licences including the restriction of Article 5(7)(a) of Regulation No 2407/92

Name of air carrier	Address of air carrier	Permitted to carry	Decision effective since
Top Speed Verband der allgemeinen Luftfahrt	A-1030 Wien, Weissgerberlände 50/12	passengers, mail, cargo	11/10/06
Flyers GmbH — Fläche	A-8073 Feldkirchen bei Graz — Flughafen Graz, Bürogebäude neu, 2.OG	passengers, mail, cargo	9.10.2006

SPAIN

Operating licences granted

Category B: Operating licences including the restriction of Article 5(7)(a) of Regulation No 2407/92

Name of air carrier	Address of air carrier	Permitted to carry	Decision effective since
Aeródromo de la Mancha, S.I	Centro de Carga Aérea, Calle 5 Norte, Parcela 1.4b, Nave 2, Aeropuerto de Madrid/Barajas 28042 Madrid	passengers, mail, cargo	17.7.2006

PORTUGAL

Operating licences revoked

Category A: Operating licences without the restriction of Article 5(7)(a) of Regulation No 2407/92

Name of air carrier	Address of air carrier	Permitted to carry	Decision effective since
Air Luxor, SA	Av. Republica, 26 1050-192 Lisboa	Passangers, cargo, freight	15.09.06

[1] OJ L 240, 24.8.1992, p. 1.
[2] Communicated to the European Commission before 31.8.2005

SWEDEN

Operating licences granted

Category A: Operating licences without the restriction of Article 5(7)(a) of Regulation No 2407/92

Name of air carrier	Address of air carrier	Permitted to carry	Decision effective since
Nordic Airways AB 556647-3541	Frösundaviks Allé 15 S-169 70 Solna	passengers, mail, cargo	30/06/06

Operating licences revoked

Category A: Operating licences without the restriction of Article 5(7)(a) of Regulation No 2407/92

Name of air carrier	Address of air carrier	Permitted to carry	Decision effective since
Falcon Air AB 556204-3702	Box 36 S-230 32 Malmö-Sturup	passengers, mail, cargo	25/09/06
Swe Fly AB 556490-0271	Box 627 S-611 10 Nyköping	passengers, mail, cargo	25/09/06

Commission communication in the framework of the implementation of the Council Directive 87/404/EEC of 25 June 1987 on the harmonization of the laws of the Member States relating to simple pressure vessels

(2006/C 287/06)

(Text with EEA relevance)

(Publication of titles and references of harmonised standards under the directive)

ESO [1]	Reference and title of the harmonised standard (and reference document)	Reference of superseded standard	Date of cessation of presumption of conformity of superseded standard Note 1
CEN	EN 286-1:1998 Simple unfired pressure vessels designed to contain air or nitrogen — Part 1: Pressure vessels for general purposes	EN 286-1:1991	Date Expired (31.8.1998)
	EN 286-1:1998/A1:2002	Note 3	Date Expired (31.1.2003)
	EN 286-1:1998/A2:2005	Note 3	Date Expired (30.4.2006)
	EN 286-1:1998/AC:2002		
CEN	EN 286-2:1992 Simple unfired pressure vessels designed to contain air or nitrogen — Part 2: Pressure vessels for air braking and auxiliary systems for motor vehicles and their trailers	—	
	EN 286-2:1992/AC:1992		
CEN	EN 286-3:1994 Simple unfired pressure vessels designed to contain air or nitrogen — Part 3: Steel pressure vessels designed for air braking equipment and auxiliary pneumatic equipment for railway rolling stock	—	
CEN	EN 286-4:1994 Simple unfired pressure vessels designed to contain air or nitrogen — Part 4: Aluminium alloy pressure vessels designed for air braking equipment and auxiliary pneumatic equipment for railway rolling stock	—	
CEN	EN 287-1:2004 Qualification test of welders — Fusion welding — Part 1: Steels	—	
	EN 287-1:2004/A2:2006	Note 3	Date Expired (30.9.2006)
	EN 287-1:2004/AC:2004		
CEN	EN 571-1:1997 Non destructive testing — Penetrant testing — Part 1: General principles	—	

ESO (1)	Reference and title of the harmonised standard (and reference document)	Reference of superseded standard	Date of cessation of presumption of conformity of superseded standard Note 1
CEN	EN 583-1:1998 Non-destructive testing — Ultrasonic examination — Part 1: General principles	—	
CEN	EN 970:1997 Non-destructive examination of fusion welds — Visual examination	—	
CEN	EN 1011-1:1998 Welding — Recommendations for welding of metallic materials — Part 1: General guidance for arc welding	—	
CEN	EN 1290:1998 Non-destructive examination of welds — Magnetic particle examination of welds	—	
CEN	EN 1330-3:1997 Non-destructive testing — Terminology — Part 3: Terms used in industrial radiographic testing	—	
CEN	EN 1714:1997 Non-destructive examination of welds — Ultrasonic examination of welded joints	—	
CEN	EN ISO 6520-1:1998 Welding and allied processes — Classification of geometric imperfections in metallic materials — Part 1: Fusion welding (ISO 6520-1:1998)	EN 26520:1991	Date Expired (30.4.1999)
CEN	EN 10207:2005 Steels for simple pressure vessels — Technical delivery requirements for plates, strips and bars	—	
CEN	EN 12062:1997 Non-destructive examination of welds — General rules for metallic materials	—	
CEN	EN ISO 15614-1:2004 Specification and qualification of welding procedures for metallic materials — Welding procedure test — Part 1: Arc and gas welding of steels and arc welding of nickel and nickel alloys (ISO 15614-1:2004)	—	
CEN	EN ISO 15614-2:2005 Specification and qualification of welding procedures for metallic materials — Welding procedure test — Part 2: Arc welding of aluminium and its alloys (ISO 15614-2:2005)	—	

(1) (1) ESO: European Standardisation Organisation:
— CEN: rue de Stassart 36, B-1050 Brussels, Tel. (32-2) 550 08 11; fax (32-2) 550 08 19 (http://www.cenorm.be)
— CENELEC: rue de Stassart 35, B-1050 Brussels, Tel. (32-2) 519 68 71; fax (32-2) 519 69 19 (http://www.cenelec.org)
— ETSI: 650, route des Lucioles, F-06921 Sophia Antipolis, Tel. (33) 492 94 42 00; fax (33) 493 65 47 16 (http://www.etsi.org)

Note 1 Generally the date of cessation of presumption of conformity will be the date of withdrawal ('dow'), set by the European Standardisation Organisation, but attention of users of these standards is drawn to the fact that in certain exceptional cases this can be otherwise.

Note 3 In case of amendments, the referenced standard is EN CCCCC:YYYY, its previous amendments, if any, and the new, quoted amendment. The superseded standard (column 3) therefore consists of EN CCCCC:YYYY and its previous amendments, if any, but without the new quoted amendment. On the date stated, the superseded standard ceases to give presumption of conformity with the essential requirements of the directive.

NOTE:

— Any information concerning the availability of the standards can be obtained either from the European Standardisation Organisations or from the national standardisation bodies of which the list is annexed to the Directive 98/34/EC [1] of the European Parliament and Council amended by the Directive 98/48/EC [2].

— Publication of the references in the *Official Journal of the European Union* does not imply that the standards are available in all the Community languages.

— This list replaces all the previous lists published in the *Official Journal of the European Union*. The Commission ensures the updating of this list.

More information about harmonised standards on the Internet at
http://europa.eu.int/comm/enterprise/newapproach/standardization/harmstds/

[1] OJ L 204, 21.7.1998, p.37.
[2] OJ L 217, 5.8.1998, p. 18.

Prior notification of a concentration

(Case COMP/M.4464 — Goldman Sachs/Cerberus/Harpen)

Candidate case for simplified procedure

(2006/C 287/07)

(Text with EEA relevance)

1. On 10 November 2006, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1] by which the undertakings Goldman Sachs Group Inc. ('Goldman Sachs', USA) and Cerberus Group ('Cerberus', USA) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the undertakings Harpen Immobilien GmbH & Co. KG and Harpen Immobilien Verwaltungsgesellschaft mbH (together 'Harpen', Germany) by way of purchase of shares in a newly created company constituting a joint venture.

2. The business activities of the undertakings concerned are:

— for undertaking Goldman Sachs: investment banking;

— for undertaking Cerberus: private equity fund;

— for undertaking Harpen: rental and development of property.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 [2] it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4464 — Goldman Sachs/Cerberus/Harpen, to the following address:

European Commission
Directorate-General for Competition
Merger Registry
J-70
B-1049 Bruxelles/Brussel

---

[1] OJ L 24, 29.1.2004, p. 1.
[2] OJ C 56, 5.3.2005, p. 32.

Guidelines on National Regional aid for 2007-2013 [1] — National regional State aid map: Latvia

(2006/C 287/08)

N 447/2006 — LATVIA

National regional State aid map 1.1.2007-31.12.2013

(Approved by the Commission on 13.09.2006)

Zone Code	Zone Name	Ceiling for regional investment aid [1] (applicable to large enterprises)
1. **Regions eligible for aid under Article 87(3)(a) of the EC Treaty until 31.12.2013**		
LV 0	LATVIA	50 %

[1] For investment projects with eligible expenditure not exceeding EUR 50 million, this ceiling is increased by 10 percentage points for medium sized companies and 20 percentage points for small companies as defined in the Commission Recommendation of 6 May 2003 concerning the definition of micro, small and medium-sized enterprises (OJ L 124, 20.5.2003, p. 36). For large investment projects with eligible expenditure exceeding EUR 50 million, this ceiling is subject to adjustment in accordance with paragraph 67 of the Guidelines on national regional aid for 2007-2013.

[1] OJ C 54, 4.3.2006, p. 13.

Prior notification of a concentration

(Case COMP/M.4168 — Österreichische Post/trans-o-flex)

Candidate case for simplified procedure

(2006/C 287/09)

(Text with EEA relevance)

1. On 14 November 2006, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1] by which the undertaking Österreichische Post AG (Austria) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of trans-o-flex GmbH (Germany) by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— for Österreichische Post AG: universal postal services, document and parcel delivery, freight forwarding; mainly in the Republic of Austria;

— for trans-o-flex GmbH: document and parcel delivery, freight forwarding, contract logistics, mainly in the Federal Republic of Germany.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 [2] it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4168 — Österreichische Post/ trans-o-flex, to the following address:

European Commission
Directorate-General for Competition
Merger Registry
J-70
B-1049 Bruxelles/Brussel

---

[1] OJ L 24, 29.1.2004, p. 1.
[2] OJ C 56, 5.3.2005, p. 32.

Non-opposition to a notified concentration

(Case COMP/M.4350 — Hewlett Packard/Mercury Interactive)

(2006/C 287/10)

(Text with EEA relevance)

On 20 October 2006, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes.

— in electronic form on the EUR-Lex website under document number 32006M4350. EUR-Lex is the online access to European law. (http://ec.europa.eu/eur-lex/lex)

Notice concerning a request in accordance with Article 30 of Directive 2004/17/EC

(2006/C 287/11)

Request made by a Member State

On 24 October 2006 the Commission received a request in accordance with Article 30(4) of Directive 2004/17/EC of the European Parliament and of the Council of 31 March 2004 coordinating the procurement procedures of entities operating in the water, energy, transport and postal services sectors ([1]).

This request, which comes from the United Kingdom, concerns the supply of electricity and gas in that country, with the exception of Northern Ireland (the request therefore concerns the supply of electricity and gas in England, Scotland and Wales). The request was published in OJ C 270 of 7 November 2006. The initial period expires on 25 January 2007.

Given that the Commission departments need to obtain and examine further information and in compliance with the provisions laid down in the third sentence of Article 30(6), the period within which the Commission must take a decision on this request is extended by one month.

The final period will therefore expire on 26 February 2006.

([1]) OJ L 134, 30.4.2004, p. 1.